Pediatric brain cancer is the most deadly childhood cancer.

The Pacific Pediatric Neuro-oncology Consortium (PNOC) brings together the world's best 275+ clinicians and researchers to push for breakthroughs.

PNOC is a consortium with a global presence with collaborating study sites in the United States, Australia, New Zealand, Switzerland, The Netherlands, Israel, Egypt and India.

Dedicated to finding cures for pediatric brain cancers, PNOC is translating the latest findings in brain tumor biology into better treatments for children.

PNOC is developing clinical trials for the deadliest pediatric brain cancers and has dedicated working groups for Diffuse Midline Glioma/High grade Glioma/DIPG, Low grade Glioma, Medulloblastoma, Atypical Teratoid Rhabdoid Tumors (ATRT), Craniopharyngioma, Ependymoma, Germ Cell Tumors as well as Immunotherapy, Imaging, and DEI (Diversity, Equity, and Inclusion).

Our doctors are disruptors and thoughtful innovators who take on highly ambitious, high-yield research.

These children can't wait. Pediatric brain cancer moves fast. We need to move faster. By raising critical research funds for the PNOC Consortium, we are accelerating research towards improved outcomes for children with brain cancer.

VISION

At the Pacific Pediatric Neuro-Oncology Consortium Foundation, our vision is to lose no child to brain cancer, and to improve the quality of life for those fighting and surviving pediatric brain cancer.

MISSION

To urgently raise funds, resources and awareness to support PNOC’s research and clinical trials, to ultimately improve outcomes for all children with brain tumors.

COLLABORATIVE

PNOC’s approach is open source and global, and is making research accessible in real time, something never before seen in this field.

BY THE NUMBERS

4,800

children are diagnosed each year, of whom more than 500 will die.

28,000

children estimated to be living with a brain tumor in the U.S.

47,000

years of life lost each year to pediatric brain cancer.

1%

despite these staggering statistics, pediatric brain cancer only receives ~1% of federal research funding.